BackgroundThe use of biologics in inflammatory bowel disease (IBD) has increased recently. However, studies on whether the proportion of IBD patient visits to the emergency department (ED) has decreased are scarce. We investigated the trends in IBD-related ED visits and hospitalization rates.MethodsMedical records of IBD-related visits to the ambulatory department (AD) and the ED of the Seoul National University Bundang Hospital in 2007, 2009, 2012, and 2014 were reviewed. Multiple-variable logistic regression analysis was used to identify significant risk factors for hospitalization.ResultsThe proportion of IBD patients who visited ED was 12.3% in 2007, 9.7% in 2009, 8.3% in 2012, and 6.4% in 2014 (P = 0.002). The most common chief complai...
Patients with inflammatory bowel disease often present to the emergency department due to the chroni...
BACKGROUND AND AIM: Variation in medical care can be an obstacle to improving quality and outcome of...
Abstract Many molecular targeted agents, including biologics, have emerged for inflammatory bowel di...
The number and proportion of patients with IBD (A), CD (B), and UC (C) treated with biologics strati...
The number and proportion of patients with IBD (A), CD (B), and UC (C) visiting ED and AD stratified...
Hospitalization rates of patients with IBD (A), CD (B), and UC (C) visiting ED stratified by years. ...
Background: Ulcerative colitis (UC) and Crohn’s Disease (CD) are the two main manifestations of infl...
Copyright © 2013 Junjie Xu et al.This is an open access article distributed under the Creative Commo...
BACKGROUND AND STUDY AIMS: In the last decade, there have been major advances in inflammatory bowel ...
OBJECTIVE: It is unclear how the compounding prevalence of inflammatory bowel disease (IBD) has tran...
Background/Aims Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s dise...
Background: Though there are many overlapping features of clinical presentations among Inflammatory ...
Inflammatory bowel diseases (IBD) [Crohn's disease (CD) and ulcerative colitis (UC)], are chronic re...
Background and aimsInflammatory bowel diseases (IBD) lead to high morbidity and unplanned healthcare...
Treatment for inflammatory bowel disease (IBD) often requires specialized care. While much of IBD ca...
Patients with inflammatory bowel disease often present to the emergency department due to the chroni...
BACKGROUND AND AIM: Variation in medical care can be an obstacle to improving quality and outcome of...
Abstract Many molecular targeted agents, including biologics, have emerged for inflammatory bowel di...
The number and proportion of patients with IBD (A), CD (B), and UC (C) treated with biologics strati...
The number and proportion of patients with IBD (A), CD (B), and UC (C) visiting ED and AD stratified...
Hospitalization rates of patients with IBD (A), CD (B), and UC (C) visiting ED stratified by years. ...
Background: Ulcerative colitis (UC) and Crohn’s Disease (CD) are the two main manifestations of infl...
Copyright © 2013 Junjie Xu et al.This is an open access article distributed under the Creative Commo...
BACKGROUND AND STUDY AIMS: In the last decade, there have been major advances in inflammatory bowel ...
OBJECTIVE: It is unclear how the compounding prevalence of inflammatory bowel disease (IBD) has tran...
Background/Aims Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s dise...
Background: Though there are many overlapping features of clinical presentations among Inflammatory ...
Inflammatory bowel diseases (IBD) [Crohn's disease (CD) and ulcerative colitis (UC)], are chronic re...
Background and aimsInflammatory bowel diseases (IBD) lead to high morbidity and unplanned healthcare...
Treatment for inflammatory bowel disease (IBD) often requires specialized care. While much of IBD ca...
Patients with inflammatory bowel disease often present to the emergency department due to the chroni...
BACKGROUND AND AIM: Variation in medical care can be an obstacle to improving quality and outcome of...
Abstract Many molecular targeted agents, including biologics, have emerged for inflammatory bowel di...